Court rules against KV in Ritalin case
NEW YORK A court has denied KV Pharmaceuticals’ motion to dismiss a suit that Celgene and Novartis brought against it alleging infringement of Celgene’s patents on attention deficit hyperactivity disorder drug Ritalin.
The two companies received notification from KV last year that the St. Louis-based drug maker had filed an application with the Food and Drug Administration for a generic version of long-acting Ritalin in 10-, 20-, 30- and 40-mg strengths. The two companies alleged that KV violated the ‘284 patents from 1998 and 2003, which Celgene licensed to Novartis and will expire in 2015.
KV attempted to have the suit thrown out, saying that attorneys for Celgene and Novartis failed to reasonably and competently conduct a pre-filing inquiry, which Federal Circuit law requires.
Ritalin (methylphenidate HCl) had sales of $375 million in 2007, according to Novartis financial data.
Gestational diabetes results in increased risk for Type 2 diabetes
NEW YORK Gestational diabetes greatly increases a woman’s risk of developing Type 2 diabetes later on in life, a new study confirms, according to Reuters.
Gestational diabetes is a known risk factor for Type 2 diabetes. Denice Feig of the University of Toronto and her team looked at 633,449 women who gave birth in Toronto between 1995 and 2002. A total of 21,823 (3.3 percent) of the women were diagnosed with gestational diabetes.
While just 2 percent of the women who didn’t have gestational diabetes went on to develop Type 2 diabetes during the 9-year follow-up period, 19 percent of those with gestational diabetes did, the researchers found.
Moreover, they say the strongest risk factor for Type 2 diabetes was gestational diabetes, which increased risk more than 37-fold.
Russian antihistamine appears effective against Alzheimer’s
NEW YORK A study that lasted a year and a half has found that an antihistamine developed in the former Soviet Union may be able to stabilize Alzheimer’s disease.
The study, presented at the International Conference on Alzheimer’s Disease, found that the drug Dimebon could stabilize the disease for at least the time of the study. Researchers tested the drug against a placebo in 183 patients in Russia who had mild to moderate Alzheimer’s.
Conditions of patients who received the placebo deteriorated, while those of the people who received Dimebon improved or deteriorated only slightly.